our science
revolutionizing neurodegenerative treatments with iPSC
We take a unique approach to drug discovery and development from current therapeutic offerings for neurodegenerative conditions by leveraging induced pluripotent stem cell (iPSC) technology, a Nobel Prize-winning scientific breakthrough, to advance new cell replacement and gene-modified medicines for the treatment of neurodegenerative conditions.
Our investigational treatments have the potential to reverse disease progression in inherited and idiopathic forms of Parkinson’s disease and other central nervous system conditions by replacing neurons and reestablishing dopamine-producing circuits in the brain.
OUR PROPRIETARY iPSC PLATFORM ENABLES:
Allogenic, donor-derived therapies scalable across patients
A cryopreserved, reproducible off-the-shelf product
our pipeline
We are advancing a pipeline of neuron replacement cell therapies and gene-modified medicines for Parkinson’s disease, designed to lost neurons, repair neural circuitry and restore motor function in people living with Parkinson’s disease. RNDP-001, our lead candidate, is an iPSC dopamine progenitor for the treatment of both idiopathic and inherited forms of Parkinson’s disease, and has displayed superior survival, innervation, and behavioral rescue in preclinical models of Parkinson’s diseases.
PROGRAM / INDICATIONS
RNDP-001
-
RNDP-001 is an iPSC-based dopamine progenitor cell for the treatment of Parkinson’s disease. RNDP-001 is designed to replace lost neurons, repair injured neural circuitry and restore motor function and is being studied in two forms of Parkinson’s disease: moderate to moderate-severe idiopathic and inherited, or autosomal recessive.
Moderate to Moderate-Severe Idiopathic Parkinson's Disease
DISCOVERY
PRE-CLINICAL
IND-ENABLING
PHASE ONE
Moderate to Moderate-Severe Autosomal Recessive Parkinson's Disease
RNDP-002
-
RNDP-002 is a gene-modified iPSC-based cell therapy that is designed to resurrect injured cells and provide new functionality to reverse the course of disease in people with mild to severe forms of Parkinson’s disease.
Mild-Severe and Rapid Progressing Parkinson's Disease
RNDP-003
-
RNDP-003 is a gene-modified iPSC therapy that is designed to address an enzymatic deficiency caused by a genetic variant that leads to Parkinson’s disease.
Early Onset Parkinson’s Disease
RNDP-001
-
RNDP-001 is an iPSC-based dopamine progenitor cell for the treatment of Parkinson’s disease. RNDP-001 is designed to replace lost neurons, repair injured neural circuitry and restore motor function and is being studied in two forms of Parkinson’s disease: moderate to moderate-severe idiopathic and inherited, or autosomal recessive.
Moderate to Moderate-Severe Idiopathic Parkinson's Disease
Moderate to Moderate-Severe Autosomal Recessive Parkinson's Disease
-
RNDP-002 is a gene-modified iPSC-based cell therapy that is designed to resurrect injured cells and provide new functionality to reverse the course of disease in people with mild to severe forms of Parkinson’s disease.
RNDP-002
Mild-Severe and Rapid Progressing Parkinson's Disease
RNDP-003
-
RNDP-003 is a gene-modified iPSC therapy that is designed to address an enzymatic deficiency caused by a genetic variant that leads to Parkinson’s disease.
Early Onset Parkinson’s Disease